![Marcella Ruddy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marcella Ruddy
Director/Board Member at POLAREAN IMAGING PLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Alise Reicin | M | 63 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | 4 years |
Kenneth West | M | - | - | |
Bastiaan Driehuys | M | - | - | |
Timothy Springer | M | 76 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Andrew Kruse | M | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Christopher von Jako | M | 53 | 1 years | |
Eran Perry | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 years |
Bill Blair | M | 69 | 1 years | |
Charles Osborne | M | 58 | 5 years | |
Stephen Austin | M | 57 | 6 years | |
Jürgen Laucht | M | - | - | |
Chen-Ming Yu | M | 50 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 years |
Cyrille Yann Nicolas Petit | M | 54 | 4 years | |
Ronald Renaud | M | 55 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | - |
Stefan Vitorovic | M | 39 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Alex Rosen | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 years |
Praveen Tipirneni | M | 55 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Frank Schulkes | M | 62 | 2 years | |
Alex Dusek | M | - | 5 years | |
Terry Mcguire | M | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Edd Fleming | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 years |
Daniel Brague | M | 56 | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Claris Hullihen | M | - | - | |
Christian Cortis | M | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | - |
Bernard Davitian | M | 63 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 13 | 52.00% |
United Kingdom | 12 | 48.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marcella Ruddy
- Personal Network